Form 8-K - Current report:
SEC Accession No. 0001213900-22-027389
Filing Date
2022-05-17
Accepted
2022-05-17 06:10:25
Documents
14
Period of Report
2022-05-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea160073-8k_abvcbio.htm   iXBRL 8-K 28129
2 OPINION OF HUNTER TAUBMAN FISCHER & LI LLC ea160073ex5-1_abvcbio.htm EX-5.1 20017
6 GRAPHIC ex5-1_001.jpg GRAPHIC 6740
  Complete submission text file 0001213900-22-027389.txt   236474

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abvc-20220516.xsd EX-101.SCH 3039
4 XBRL LABEL FILE abvc-20220516_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE abvc-20220516_pre.xml EX-101.PRE 22599
8 EXTRACTED XBRL INSTANCE DOCUMENT ea160073-8k_abvcbio_htm.xml XML 3496
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 22932163
SIC: 2834 Pharmaceutical Preparations